Jessica Madigan and Normand Blais discuss the steps that BIOVECTRA has taken to reduce the risks associated with mRNA development and manufacturing, including using automation combined with a quality-by-design approach for process optimization, developing in-house analytical methods, and monitoring the evolution of new technology and regulations in the space.
.svg)
